Loading clinical trials...
Loading clinical trials...
A DB, Randomized, Placebo-controlled Study of the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial CLBS14 for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Conditions
Interventions
CLBS14 (low-dose)
CLBS14 (high-dose)
+1 more
Locations
26
United States
Cardiology PC
Birmingham, Alabama, United States
Arizona Heart Institute
Phoenix, Arizona, United States
Mayo Clinic Hospital
Phoenix, Arizona, United States
Scripps Memorial Hospital
La Jolla, California, United States
Stanford University Hospital and Clinics
Stanford, California, United States
Washington Hospital Center
Washington D.C., District of Columbia, United States
Start Date
April 1, 2006
Primary Completion Date
March 1, 2008
Completion Date
March 1, 2009
Last Updated
January 26, 2021
NCT06535568
NCT05865600
NCT05846893
NCT06255769
NCT05248165
NCT05584280
Lead Sponsor
Lisata Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions